Pain Medicine Combination and Uses Thereof

Abstract

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.

1 - 51 . (canceled) 
     
     
         52 . A pharmaceutical dosage form comprising:
 a NMDA antagonist;   a CYP2D6 inhibitor; and   morphine, or a pharmaceutically acceptable salt thereof.   
     
     
         53 . The pharmaceutical dosage form of  claim 52 , wherein the NMDA antagonist is selected from the group consisting of: dextromethorphan, a glycine antagonist, ifenprodil like compound, amantadine, MK-801 (dizocilpine; [5R, 10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine), ketamine, memantine, D-AP5 (D(−)-2-Amino-5-phosphonovaleric acid) and CPP (3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid), or a pharmaceutically acceptable salt thereof, or any combination thereof. 
     
     
         54 . The pharmaceutical dosage form of  claim 52 , wherein the NMDA antagonist is dextromethorphan, or a pharmaceutically acceptable salt thereof. 
     
     
         55 . The pharmaceutical dosage form of  claim 52 , wherein the NMDA antagonist is dextromethorphan hydrobromide monohydrate. 
     
     
         56 . The pharmaceutical dosage form of  claim 52 , wherein the CYP2D6 inhibitor is quinidine, or a pharmaceutically acceptable salt thereof. 
     
     
         57 . The pharmaceutical dosage form of  claim 52 , wherein the CYP2D6 inhibitor is quinidine gluconate or quinidine sulfate. 
     
     
         58 . The pharmaceutical dosage form of  claim 52 , wherein the ratio of the morphine to NMDA antagonist is about 1:1 (wt:wt). 
     
     
         59 . The pharmaceutical dosage form of  claim 52 , wherein the ratio of the morphine to CYP2D6 inhibitor is about 1:0.1 to 1 (wt:wt). 
     
     
         60 . The pharmaceutical dosage form of  claim 52 , wherein the ratio of the morphine to CYP2D6 inhibitor is about 0.1-1:1 (wt:wt). 
     
     
         61 . The pharmaceutical dosage form of  claim 52 , wherein the ratio of the morphine to NMDA antagonist to CYP2D6 inhibitor is about 1:1:0.1-1 (wt:wt:wt). 
     
     
         62 . The pharmaceutical dosage form of  claim 52 , wherein the ratio of the morphine to NMDA antagonist to CYP2D6 inhibitor is about 1:1:1 (wt:wt:wt). 
     
     
         63 . The pharmaceutical dosage form of  claim 52 , wherein the morphine is morphine sulfate. 
     
     
         64 . A method of preparing the pharmaceutical dosage form of  claim 52 , the method comprising mixing the NMDA antagonist, the CYP2D6 inhibitor; and the morphine, or a pharmaceutically acceptable salt thereof, and forming the mixture into the pharmaceutical dosage form. 
     
     
         65 . The method of  claim 64 , wherein the dosage form is a tablet or a capsule. 
     
     
         66 . A method of treating pain in a subject, the method comprising administering to the subject the pharmaceutical dosage form of  claim 52 . 
     
     
         67 . The method of  claim 66 , wherein the dosage form is a tablet. 
     
     
         68 . The method of  claim 67 , wherein the dosage form is a capsule.